Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04300556
Title A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eisai Inc.
Age Groups: senior | adult
Covered Countries USA | GBR | FRA | ESP

No variant requirements are available.